121 related articles for article (PubMed ID: 16331501)
1. Anti-tumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces single-strand breaks and DNA-protein cross-links in sensitive MCF-7 breast cancer cells.
Brantley E; Antony S; Kohlhagen G; Meng L; Agama K; Stinson SF; Sausville EA; Pommier Y
Cancer Chemother Pharmacol; 2006 Jul; 58(1):62-72. PubMed ID: 16331501
[TBL] [Abstract][Full Text] [Related]
2. DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells.
Trapani V; Patel V; Leong CO; Ciolino HP; Yeh GC; Hose C; Trepel JB; Stevens MF; Sausville EA; Loaiza-Pérez AI
Br J Cancer; 2003 Feb; 88(4):599-605. PubMed ID: 12592376
[TBL] [Abstract][Full Text] [Related]
3. Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.
Leong CO; Gaskell M; Martin EA; Heydon RT; Farmer PB; Bibby MC; Cooper PA; Double JA; Bradshaw TD; Stevens MF
Br J Cancer; 2003 Feb; 88(3):470-7. PubMed ID: 12569393
[TBL] [Abstract][Full Text] [Related]
4. In vitro, in vivo, and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles.
Leong CO; Suggitt M; Swaine DJ; Bibby MC; Stevens MF; Bradshaw TD
Mol Cancer Ther; 2004 Dec; 3(12):1565-75. PubMed ID: 15634650
[TBL] [Abstract][Full Text] [Related]
5. Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.
Brantley E; Trapani V; Alley MC; Hose CD; Bradshaw TD; Stevens MF; Sausville EA; Stinson SF
Drug Metab Dispos; 2004 Dec; 32(12):1392-401. PubMed ID: 15355884
[TBL] [Abstract][Full Text] [Related]
6. Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human Breast Cancer Cells.
McLean LS; Watkins CN; Campbell P; Zylstra D; Rowland L; Amis LH; Scott L; Babb CE; Livingston WJ; Darwanto A; Davis WL; Senthil M; Sowers LC; Brantley E
Chem Res Toxicol; 2015 May; 28(5):855-71. PubMed ID: 25781201
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl)benzothiazole in breast cancer cell lines.
Bradshaw TD; Stone EL; Trapani V; Leong CO; Matthews CS; te Poele R; Stevens MF
Breast Cancer Res Treat; 2008 Jul; 110(1):57-68. PubMed ID: 17674193
[TBL] [Abstract][Full Text] [Related]
8. The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.
Brantley E; Patel V; Stinson SF; Trapani V; Hose CD; Ciolino HP; Yeh GC; Gutkind JS; Sausville EA; Loaiza-Pérez AI
Anticancer Drugs; 2005 Feb; 16(2):137-43. PubMed ID: 15655410
[TBL] [Abstract][Full Text] [Related]
9. Genotoxic profiling of MCF-7 breast cancer cell line elucidates gene expression modifications underlying toxicity of the anticancer drug 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole.
Monks A; Harris E; Hose C; Connelly J; Sausville EA
Mol Pharmacol; 2003 Mar; 63(3):766-72. PubMed ID: 12606787
[TBL] [Abstract][Full Text] [Related]
10. CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells.
Tan BS; Tiong KH; Muruhadas A; Randhawa N; Choo HL; Bradshaw TD; Stevens MF; Leong CO
Mol Cancer Ther; 2011 Oct; 10(10):1982-92. PubMed ID: 21831963
[TBL] [Abstract][Full Text] [Related]
11. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Takebayashi Y; Goldwasser F; Urasaki Y; Kohlhagen G; Pommier Y
Clin Cancer Res; 2001 Jan; 7(1):185-91. PubMed ID: 11205907
[TBL] [Abstract][Full Text] [Related]
12. The antitumour activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole in human gastric cancer models is mediated by AhR signalling.
Wang Y; Liu Y; Tang T; Luo Y; Stevens MFG; Cheng X; Yang Y; Shi D; Zhang J; Bradshaw TD
J Cell Mol Med; 2020 Jan; 24(2):1750-1759. PubMed ID: 31876059
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of acquired resistance to 2-(4-aminophenyl)benzothiazole (CJM 126, NSC 34445).
Bradshaw TD; Chua MS; Orr S; Matthews CS; Stevens MF
Br J Cancer; 2000 Jul; 83(2):270-7. PubMed ID: 10901382
[TBL] [Abstract][Full Text] [Related]
14. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
15. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
16. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
[TBL] [Abstract][Full Text] [Related]
17. Role of Cyp1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells.
Chua MS; Kashiyama E; Bradshaw TD; Stinson SF; Brantley E; Sausville EA; Stevens MF
Cancer Res; 2000 Sep; 60(18):5196-203. PubMed ID: 11016648
[TBL] [Abstract][Full Text] [Related]
18. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
Poddevin B; Riou JF; Lavelle F; Pommier Y
Mol Pharmacol; 1993 Oct; 44(4):767-74. PubMed ID: 8232227
[TBL] [Abstract][Full Text] [Related]
19. New tanshinone I derivatives S222 and S439 similarly inhibit topoisomerase I/II but reveal different p53-dependency in inducing G2/M arrest and apoptosis.
Tian QT; Ding CY; Song SS; Wang YQ; Zhang A; Miao ZH
Biochem Pharmacol; 2018 Aug; 154():255-264. PubMed ID: 29753750
[TBL] [Abstract][Full Text] [Related]
20. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
